|
Tragara is a pharmaceutical company based in San Diego, California
focused on the clinical and commercial development of proprietary
drugs for the treatment of various cancers. Tragara is focusing
its development efforts on two proprietary compounds: (1) CapoxigemŽ
(apricoxib; TG01), an oral once-daily, potent, and selective
inhibitor of cyclooxygenase-2 (COX-2) for the treatment of solid
tumors including non-small cell lung cancer, breast cancer,
and pancreatic cancer and (2) TG02- multikinase inhibitor for
the treatment of hematologic and solid tumors.
Tragara is managed by a team of entrepreneurs with both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics.
|
